Market News & Trends
Ajinomoto Bio-Pharma Services Signs Manufacturing Agreement With Humanigen for Lenzilumab, Currently in FDA-Approved Phase 3 Study for COVID-19
Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, recently announced it has entered into a manufacturing agreement with Humanigen, Inc.,…
KBP Biosciences Completes Enrollment of BLOCK CKD Phase 2b Study
KBP Biosciences recently announced it has completed patient enrollment of BLOCK CKD (Blood Pressure in Chronic Kidney Disease), its Phase 2b study of its lead…
Alethia Biotherapeutics Announces Receipt of FDA Authorization to Begin Phase 2 Development
Alethia Biotherapeutics recently announced the US FDA has cleared its Phase 2 Investigational new drug (IND) application for AB-16B5, a potent inhibitor of the epithelial…
Catalent Announces Acquisition of Japanese Facility to Provide Local & Global Clinical Supply Solutions
Catalent recently announced a deal to acquire a clinical packaging facility in Minakuchi, located in the Shiga prefecture of Japan, from Teva-Takeda Pharmaceuticals, Nagoya Aichi,…
eGenesis Strengthens Production Capabilities With Acquisition of ICBiotec
eGenesis recently announced the acquisition of the assets and operations of ICBiotec (ICB), one of its key production partners. ICB is one of the few…
Vaxart Announces Selection of its Oral COVID-19 Vaccine Lead Candidate
Vaxart, Inc. recently announced it has selected its lead COVID-19 vaccine candidate and has contracted with KindredBio to manufacture bulk vaccine under cGMP to complement…
Apollomics Announces Initiation of SPARTA Phase 2 Clinical Trial
Apollomics, Inc. recent announced the initiation of the Phase 2 portion of the Phase 1/2 clinical trial for APL-101 based on completion of the Phase 1 and approval from the….
FDA Approves Octapharma USA Investigational New Drug Application for Severe COVID-19 Patients
The US FDA has recently approved the investigational new drug (IND) application submitted by Octapharma USA for a Phase 3 clinical trial on…
SeraNovo Enters Second License Agreement With Carna Biosciences
SeraNovo B.V. recently announced it has signed a second License Agreement with Carna Biosciences, Inc., a company engaged in the drug development of….
CanSino Biologics & Precision NanoSystems Announce Collaboration to Co-Develop a COVID-19 RNA Vaccine
CanSino Biologics Inc. and Precision NanoSystems (PNI) recently announced a co-development agreement of a mRNA lipid nanoparticle (mRNA-LNP) vaccine against COVID-19. The parties will…
CureVac´s Optimized mRNA Platform Provides Positive PreClinical Results at Low Dose for COVID-19 Vaccine Candidate
CureVac AG recently announced positive preclinical results at a low dose for its lead vaccine candidate against the novel Coronavirus (SARS-CoV-2). The data showed a…
Almac Discovery Enters Into Licensing Agreement for the Development & Commercialization of ALM301
Almac Discovery, a member of the Almac Group, recently announced an out-licensing partnership with an undisclosed biotechnology company in order to advance the development and…
Cue Biopharma Announces Strategic Research Collaboration
Cue Biopharma, Inc. recently announced it has entered into a research collaboration agreement with Dr. Michael Dustin and the University of Oxford to determine the…
Triphase Accelerator & Catalent Announce Interim Results of a Dose Escalation Phase 1 Clinical Trial
Triphase Accelerator and Catalent recently announced interim results for Triphase Accelerator's multi-center, open-label, monotherapy study of TRPH-222 in heavily pre-treated patients with relapsed and/or refractory…
ChemoCentryx & VFMCRP Announce Topline Data from Phase 2 LUMINA-1 Trial
ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) recently announced topline data from a 46-patient Phase 2 dose-ranging trial in the orphan kidney…
Krystal Biotech Announces Positive Interim Results from Phase 1/2 Clinical Trial
Krystal Biotech, Inc. recently announced interim results for a first-in-human Phase 1/2 placebo controlled clinical trial evaluating topical administration of KB105 in patients with autosomal…
MD Anderson & Innovent Biologics Announce Strategic Rare Cancer Development Collaboration
The University of Texas MD Anderson Cancer Center and Innovent Biologics, Inc. recently announced a strategic collaboration agreement to co-develop TYVYT (sintilimab injection), Innovent’s anti-PD-1 monoclonal…
Taconic Biosciences Launches Rapid Restart Program
Taconic Biosciences, a global leader in providing drug discovery animal model solutions, recently announced the successful implementation of its Rapid Restart program….
COVID-19’s Effect Will Boost Infectious Disease Drug Approvals & Present Opportunities to CMOs
In response to the global pandemic, biopharma companies have put a renewed emphasis on finding treatments for infectious diseases, including COVID-19 and other infectious diseases overall…..
Akers Biosciences & Premas Biotech Announce Successful Completion of COVID-19 Vaccine Prototype & Obtained First Images of VLP
Akers Biosciences, Inc. recently announced that Premas Biotech, its partner in the development of a vaccine candidate that is seeking to address the COVID-19 pandemic…..
